Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654214 | 0.97 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10395286 | 0.95 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL9654517 | 0.93 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10394508 | 0.93 | CYP3A4 (0.56) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10395237 | 0.92 | LPAR3 (0.58) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10395209 | 0.91 | CYP3A4 (0.54) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL10395698 | 0.91 | CYP3A4 (0.54) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL6352746 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL10395224 | 0.90 | LPAR3 (0.61) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL10394494 | 0.88 | LPAR3 (0.54) | CYP3A4LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024053596-A1 | METHOD FOR RECOVERING SCANDIUM | 日本製鉄株式会社 | 2024-03-14 | — | — | WO | disclosed |
| US-20240018173-A1 | PROCESS FOR PREPARING PHOSPHONATE ESTERS | ENTEGRIS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2024015263-A1 | PROCESS FOR PREPARING PHOSPHONATE ESTERS | ENTEGRIS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20150291636-A1 | ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | LABORATOIRE BIODIM (FR) | 2015-10-15 | — | — | US | disclosed |
| US-7638637-B2 | Immunomodulators; amino-functional imidazole phosphonates and analogues thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| US-20050234257-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO | 2005-10-20 | — | — | US | disclosed |
| US-6909010-B2 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO (US) | 2005-06-21 | — | — | US | disclosed |
| CN-1561219-A | Pharmaceutical compounds | ILEX ONCOLOGY INC (CH) | 2005-01-05 | — | — | CN | disclosed |
| EP-1326618-A2 | USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES | Ilex Oncology Research S.A. (CH) | 2003-07-16 | — | — | EP | disclosed |
| EP-0479813-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES. | HUHTAMAEKI YHTHYMAE OY (FI) | 1992-04-15 | — | — | EP | disclosed |
| US-5043330-A | Antiinflammatory and hypotensive agents; antihyperlipemia | SYMPHAR S.A. (CH) | 1991-08-27 | — | — | US | disclosed |
| EP-0418064-A2 | Naphthalene and tetrahydronaphthalene gem-diphosphonate derivatives | SYMPHAR S.A. (CH) | 1991-03-20 | — | — | EP | disclosed |
| WO-1990015806-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | Huhtamäki Oy (FI) | 1990-12-27 | — | — | WO | disclosed |
| US-4939284-A | Process for the manufacture of tetraalkyl ethenylidenebisphosphonate esters | THE PROCTER & GAMBLE COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0339237-A2 | Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them | SYMPHAR S.A. (CH) | 1989-11-02 | — | — | EP | disclosed |
| US-4820698-A | TETRAALKYL ETHENYLIDENEBISPHOSPHONATES | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| US-4419440-A | Process for the introduction of hydrophobic photographic additives | VEB FILMFABRIK WOLFEN (DD) | 1983-12-06 | — | — | US | disclosed |
| US-4141967-A | ANHYDROUS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1979-02-27 | — | — | US | disclosed |
| US-4009116-A | Process of preparing substantially organic waste liquids containing radioactive or toxic substances for safe, non-pollutive handling, transportation and permanent storage | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | S1PR3, S1PR1, S1PR5 | CYP3A4 1863/4885LPAR3 8/4885LPAR1 10/4885 |
| US-20240018173-A1 | PROCESS FOR PREPARING PHOSPHONATE ESTERS | MED1, MED16, MED12 | CYP3A4 3360/4885LPAR3 1350/4885LPAR1 1240/4885 |
| US-20050234257-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | PHOSPHO1, PAPSS1, PHPT1 | CYP3A4 323/4885LPAR3 977/4885LPAR1 554/4885 |
| US-20150291636-A1 | ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | C3AR1, CFH, MSR1 | CYP3A4 3271/4885LPAR3 599/4885LPAR1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.